Nowarta 110

Drug Profile

Nowarta 110

Alternative Names: Nowarta110

Latest Information Update: 15 Apr 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Nowarta Biopharma
  • Class Antivirals
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Warts

Most Recent Events

  • 01 Dec 2015 Nowarta Biopharma completes a phase I/II trial in Warts (Recurrent) in USA (unspecified route) (NCT02338336)
  • 13 Jan 2015 Clinical trials in Warts (unspecified route)
  • 13 Jan 2015 Nowarta Biopharma plans a phase I/II trial for Warts in USA (NCT02338336)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top